QCLS on Nasdaq

Q/C TECHNOLOGIES, INC.

American in vitro and in vivo diagnostic substances company based in New York.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Celldex Therapeutics, VOLITIONRX LTD or Insight Molecular Diagnostics Inc., or pick any stock.

TickerQCLS on Nasdaq
IndustryIn Vitro & In Vivo Diagnostic Substances
HeadquartersDE
Incorporated inDE²
Business address1185 Avenue Of The Americas, Suite 249, New York, Ny 10036²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

30.4%Gross margin³

-220.2%Operating margin⁴

-246.6%Net margin⁴

Where the money goes

Where each dollar of revenue went, fiscal 2019

Research and developmentOther costs

Cost of revenue3¢$46.5K
Research and development18¢$276.8K
Other costs79¢$1.3M

Out of $1.6M in revenue.⁵³⁴ The company lost money this year.

Financial statements

Fiscal year	2019
Revenue	$1.6M⁵
Cost of revenue	$46.5K³
Gross profit	$478.7K³
Research and development	$276.8K³
Operating income	-$3.5M⁴
Income tax
Net income	-$3.9M⁴
Earnings per share
Earnings per share (diluted)

Fiscal year	2019
Cash	$517.4K⁴
Current assets	$10.3M⁴
Total assets	$10.9M⁴
Current liabilities	$1.5M⁴
Total liabilities	$1.5M⁴
Shareholders’ equity	-$2.3M⁸
Shares outstanding	1.7M shares⁴

Fiscal year	2019
Cash from operations	-$3.1M⁴
Capital spending
Free cash flow

Compare Q/C TECHNOLOGIES, INC. with another company

Leadership

Who has led Q/C TECHNOLOGIES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

201520202025

Chief executive officerHoward Yeaton Oct 16, 2018 to Oct 3, 2019⁹
Chief executive officerJohn J. Gormally Dec 29, 2015 to Apr 10, 2018¹⁰
Chief executive officerThomas Albert Nicolette Jan 24, 2014 to Jan 24, 2014¹¹
ChairChristopher C. Schreiber Jan 3, 2020 to Sep 11, 2020¹²
ChairRaymond Francis Akers Jr. Jan 24, 2014 to Jan 6, 2016¹³
PresidentMitchell Glass Apr 18, 2025 to now¹⁴
PresidentChristopher C. Schreiber Sep 11, 2020 to Sep 11, 2020¹⁵
PresidentThomas Albert Nicolette Jan 24, 2014 to Jan 24, 2014¹¹
Chief financial officerCharles Todd Fagan Aug 17, 2026 to now¹⁶
Chief financial officerIan Rhodes Feb 11, 2021 to Aug 17, 2026¹⁷
Chief financial officerHoward Yeaton Oct 16, 2018 to Oct 3, 2019⁹

Board members and other officers (21)

Chief Technology OfficerYossef Ehrlichman Sep 22, 2026 to now¹⁸
Director, Chief Medical Off.Mitchell Glass Oct 6, 2025 to now¹⁹
EVP of Operations, GCPaul Rivard Apr 20, 2021 to Dec 8, 2022²⁰
Chief Scientific OfficerAdam Kaplin Apr 21, 2021 to Jun 9, 2023²¹
Controller, TreasurerGary M. Rauch Jan 24, 2014 to Oct 24, 2017²²
Board memberChelsea Sierra Voss Jan 30, 2026 to now²³
Board memberMitchell Glass May 16, 2024 to now²⁴
Board memberStephen Friscia Jun 28, 2024 to now²⁵
Board memberJude Uzonwanne Apr 21, 2021 to Jun 9, 2023²⁶
Board memberCraig Eagle Apr 22, 2021 to Jun 9, 2023²⁷
Board memberRobert C. Schroeder Nov 7, 2019 to Apr 20, 2021²⁸
Board memberRichard C. Tarbox Iii. Apr 10, 2018 to Apr 10, 2018²⁹
Board memberChristopher C. Schreiber Sep 21, 2018 to Jun 9, 2023³⁰
Board memberJohn J. Gormally Oct 24, 2017 to Apr 10, 2018³¹
Board memberRobert E. Andrews Nov 20, 2015 to Dec 31, 2015³²
Board memberRaza Bokhari Dec 14, 2015 to Dec 31, 2015³³
Board memberBrandon Thomas Knox Jan 24, 2014 to Feb 13, 2017³⁴
Board memberGavin Moran Jan 24, 2014 to Jan 12, 2015³⁵
Board memberThomas Albert Nicolette Jan 24, 2014 to Jan 24, 2014¹¹
Board memberThomas J. Knox Jan 24, 2014 to Jan 5, 2016³⁶
General counselPaul Rivard Jun 9, 2023 to Aug 24, 2023³⁷

Former names

TNF Pharmaceuticals, Inc.Jun 27, 2024 to Sep 10, 2025²
MyMD Pharmaceuticals, Inc.Apr 16, 2021 to Jul 1, 2024²
Akers Biosciences, Inc.Apr 13, 2017 to Apr 16, 2021²
Akers Biosciences IncMar 23, 2005 to Apr 11, 2017²

Timeline

Oct 16, 2018New chief executive Howard Yeaton becomes CEO⁹
Dec 29, 2015New chief executive John J. Gormally becomes CEO¹⁰
Jan 24, 2014New chief executive Thomas Albert Nicolette becomes CEO¹¹

Filings

222 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 80 major events, 54 insider forms, 10 large holders, 4 private raises, 52 other. The latest 20:

Oct 2, 20264 EDGAR
Oct 2, 20264/A EDGAR
Sep 22, 20263 EDGAR
Sep 18, 20268-K EDGAR
Sep 11, 20268-K EDGAR
Aug 17, 20263 EDGAR
Aug 12, 202610-Q EDGAR
Jul 2, 20268-K EDGAR
May 15, 202610-Q EDGAR
May 14, 20264 EDGAR
Apr 29, 202610-K/A EDGAR
Apr 15, 20264 EDGAR
Apr 15, 20264 EDGAR
Apr 15, 20264 EDGAR
Apr 15, 20264 EDGAR
Apr 15, 20264 EDGAR
Apr 15, 20264 EDGAR
Apr 15, 202610-K EDGAR
Mar 31, 2026NT 10-K EDGAR
Mar 13, 20268-K EDGAR

The 222 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 10 such filings since October 2021:

Nov 18, 2025SCHEDULE 13D/A
Nov 14, 2024SC 13G/A
May 30, 2024SC 13D
Feb 14, 2024SC 13G
Feb 14, 2024SC 13G/A
Feb 14, 2023SC 13G/A
Sep 8, 2022SC 13D
Feb 23, 2022SC 13G/A
Feb 11, 2022SC 13G/A
Jan 11, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Sep 2, 2025Raised $7 million in a private offering of equity Form D: 12 investors so far Form D
May 20, 2024Raised $26.9 million in a private offering of equity Form D: 4 investors so far Form D
May 20, 2024Raised $15.2 million in a private offering of equity Form D: 5 investors so far Form D
Aug 15, 2022Filed a private offering of securities Form D: $7.4 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Quinn Opportunity Partners LLC	123,024	$479.8K	0.0%	−88,366
Vanguard Capital Management LLC	115,031	$448.6K	0.0%	+77,520
Jane Street Group, LLC	87,241	$340.2K	0.0%	−38,947
Geode Capital Management, LLC	70,682	$275.7K	0.0%	+23,292
UBS Group AG	58,894	$229.7K	0.0%	−19,095
Balyasny Asset Management L.P.	57,692	$225.0K	0.0%	New
ADAR1 Capital Management, LLC	50,000	$195.0K	0.0%	No change
Vanguard Fiduciary Trust Co	43,053	$167.9K	0.0%	+27,498
State Street Corp	25,305	$98.7K	0.0%	+12,400
Dimensional Fund Advisors LP	19,058	$74.3K	0.0%	No change
Northern Trust Corp	17,997	$70.2K	0.0%	New
Peak6 LLC	12,778	$49.8K	0.0%	New
Tower Research Capital LLC (TRC)	1,043	$4.1K	0.0%	−550
Barclays PLC	950	$3.7K	0.0%	New
SBI Securities Co., Ltd.	100	$390	0.0%	New
Hrt Financial LP	50,373	$196	0.0%	+27,969
BlackRock, Inc.	19	$74	0.0%	No change
Caitong International Asset Management Co., Ltd	9	$35	0.0%	New
Jones Financial Companies Lllp	2	$7	0.0%	No change
Wilmington Savings Fund Society, FSB	1	$4	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARQ/C TECHNOLOGIES, INC. filings on SEC EDGAR
2
SEC EDGARQ/C TECHNOLOGIES, INC. filings on SEC EDGAR
3
SEC EDGARQ/C TECHNOLOGIES, INC. 10-K for fiscal 2019
4
SEC EDGARQ/C TECHNOLOGIES, INC. 10-K for fiscal 2019
5
SEC EDGARQ/C TECHNOLOGIES, INC. 10-K for fiscal 2019
6
SEC EDGARQ/C TECHNOLOGIES, INC. 10-Q for fiscal 2026
7
SEC EDGARQ/C TECHNOLOGIES, INC. 10-Q for fiscal 2026
8
SEC EDGARQ/C TECHNOLOGIES, INC. 10-K for fiscal 2019
9
SEC EDGARHoward Yeaton, Chief executive officer
10
SEC EDGARJohn J. Gormally, Chief executive officer
11
SEC EDGARThomas Albert Nicolette, Chief executive officer
12
SEC EDGARChristopher C. Schreiber, Chair
13
SEC EDGARRaymond Francis Akers Jr., Chair
14
SEC EDGARMitchell Glass, President
15
SEC EDGARChristopher C. Schreiber, President
16
SEC EDGARCharles Todd Fagan, Chief financial officer
17
SEC EDGARIan Rhodes, Chief financial officer
18
SEC EDGARYossef Ehrlichman, Chief Technology Officer
19
SEC EDGARMitchell Glass, Director, Chief Medical Off.
20
SEC EDGARPaul Rivard, EVP of Operations, GC
21
SEC EDGARAdam Kaplin, Chief Scientific Officer
22
SEC EDGARGary M. Rauch, Controller, Treasurer
23
SEC EDGARChelsea Sierra Voss, Board member
24
SEC EDGARMitchell Glass, Board member
25
SEC EDGARStephen Friscia, Board member
26
SEC EDGARJude Uzonwanne, Board member
27
SEC EDGARCraig Eagle, Board member
28
SEC EDGARRobert C. Schroeder, Board member
29
SEC EDGARRichard C. Tarbox Iii., Board member
30
SEC EDGARChristopher C. Schreiber, Board member
31
SEC EDGARJohn J. Gormally, Board member
32
SEC EDGARRobert E. Andrews, Board member
33
SEC EDGARRaza Bokhari, Board member
34
SEC EDGARBrandon Thomas Knox, Board member
35
SEC EDGARGavin Moran, Board member
36
SEC EDGARThomas J. Knox, Board member
37
SEC EDGARPaul Rivard, General counsel